MetaCap

Axsome Therapeutics Inc. (AXSM)

NASDAQ: AXSMHealth CareBiotechnology: Pharmaceutical PreparationsUSD

129.36-6.32 (-4.66%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

AXSM stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$3.03
52-week range
123.00 – 260.19
Day range
128.24 – 135.09
Volume / Avg
811.75K / 865.33K
Beta
—

52-week range

$123.00$260.19

AXSM stock today

Axsome Therapeutics (AXSM) closed at $129.36 on Nov 20, down 4.66% (-$6.32), versus the S&P 500's 3.70% decline. Shares are 50.3% below their 52-week high of $260.19, set on Jun 18, 2026 and 5.2% above the 52-week low of $123.00, near the bottom of the past year's range. AXSM is down 29.2% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 13.4%.

Axsome Therapeutics has posted a net loss over the last twelve months (EPS of -$3.03), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Axsome Therapeutics

Company profile

Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura. It also develops AXS-05 (dextromethorphan-bupropion), an investigational N-methyl-D-aspartate receptor antagonist, which has completed Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-12 (reboxetine), a highly selective and potent norepinephrine reuptake inhibitor and cortical dopamine modulator, which has completed Phase II trial to treat narcolepsy; AXS-14 (esreboxetine), a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and Solriamfetol, a dopamine and norepinephrine reuptake inhibitor, which is in Phase III trial for treating attention deficit hyperactivity, major depressive, binge eating, and excessive sleepiness associated with shift work disorder.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Herriot Tabuteau M.D.
Headquarters
New York, NY
Employees
1,390
IPO year
2015
Website
axsome.com

Financial highlights

Full financials

In fiscal 2025, Axsome Therapeutics generated $638.5 million in revenue, up 65.5% from fiscal 2024, its 3rd consecutive year of revenue growth. Axsome Therapeutics reported a net loss of $183.2 million, compared with a loss of $287.2 million a year earlier. Gross margin was 92.6% (up from 91.4%) and operating margin -26.1%.

Axsome Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$638.50M$385.69M$270.60M$0—
Growth+65.55%+42.53%———
Net income$-183.17M$-287.22M$-239.24M$-187.13M$-130.40M
EPS (diluted)$-3.68$-5.99$-5.27$-4.60$-3.47

Analyst forecast

Forecast

Consensus (22 analysts)

strong_buy

Avg. price target

$264.62+104.56%

  • Strong buy 3
  • Buy 18
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $220.00High $315.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 2, 2026
EPS actual vs est.
$-0.25 vs $-0.69
Surprise
+63.77%

AXSM news

All AXSM news

Axsome Therapeutics peers

Health Care sector
AXSM peer companies
CompanyPrice% ChgMarket capCompare
CORTCorcept Therapeutics Incorporated63.62-2.09%$6.96Bvs AXSM
CYTKCytokinetics Incorporated50.78-1.32%$7.07Bvs AXSM
ABVXAbivax SA ADR73.20-9.24%$6.41Bvs AXSM
MIRMMirum Pharmaceuticals Inc.96.13+0.65%$6.28Bvs AXSM
AMRXAmneal Pharmaceuticals Inc. Class A21.12-1.26%$7.36Bvs AXSM
KNSAKiniksa Pharmaceuticals International plc Class A93.90+0.38%$7.38Bvs AXSM
ALKSAlkermes plc44.94-2.69%$7.55Bvs AXSM
SUPNSupernus Inc.28.61+0.92%$5.94Bvs AXSM

Indexes, lists and sector

Axsome Therapeutics stock FAQ

What is Axsome Therapeutics's stock price today?

AXSM last traded at $129.36 as of Nov 20, 4:00 PM EST, down 4.66% on the day. Prices are delayed at least 15 minutes.

Who is Axsome Therapeutics's CEO?

Dr. Herriot Tabuteau M.D. is the chief executive officer of Axsome Therapeutics Inc., which has about 1,390 employees.

What is the AXSM 52-week high?

The 52-week high for AXSM is $260.19 and the 52-week low is $123.00. The stock is currently 50.3% below its high.

Compare AXSM